All News
Filter News
Found 808,645 articles
-
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
3/24/2021
Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA Positive new interim data from MPS IIIA and MPS IIIB programs presented at 17 th Annual WORLDSymposium
-
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
3/24/2021
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthened cash position with $627 million in net IPO proceeds
-
Stryker announces Annual Meeting of Shareholders - Mar 24, 2021
3/24/2021
Due to concerns regarding the coronavirus outbreak and to assist in protecting the health and well-being of our shareholders and employees, this year’s Annual Meeting of Shareholders of Stryker Corporation will be held virtually via the internet.
-
Award-winning Laboratory Becomes Official Health and Wellness Testing Supplier of USL
3/24/2021
The United Soccer League today announced a partnership with Premier Medical Laboratory Services (PMLS), which becomes the Official Health and Wellness Testing Supplier of USL.
-
Mettler-Toledo International Inc. Announces Acquisition Of PendoTECH
3/24/2021
Mettler-Toledo International Inc. (NYSE: MTD) today announced that it completed the acquisition of PendoTECH, a manufacturer and distributor of single-use sensors, transmitters, control systems and software for measuring, monitoring and data collection primarily in bioprocess applications.
-
Aspen Surgical Acquires BlueMed Medical Supplies
3/24/2021
Aspen Surgical Products, Inc., a leader in surgical disposable products, announced the acquisition of BlueMed Medical Supplies, Inc..
-
BioNTech Chairman Helmut Jeggle joins the Board of IQM Quantum Computers
3/24/2021
IQM Quantum Computers (IQM) announced today that Helmut Jeggle has joined IQM´s board of directors. He joins the company during a transformational phase
-
Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3/24/2021
Phase 2 studies in fibromyalgia and painful DPN enrolling as planned – data readouts expected in 1H 2022 Phase 2 study in cognitive impairment expected to recommence imminently – data readout expected in 2H 2022 Reported data from Phase 2 exploratory study of NYX-783 in PTSD, supporting further clinical development – meeting with FDA to discuss future development path April 29, 2021
-
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021
3/24/2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 30, 2021, after the close of the U.S. financial markets.
-
Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
3/24/2021
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2020.
-
ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel
3/24/2021
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021
-
TransMedics Appoints Stephanie Lovell to Board of Directors
3/24/2021
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Stephanie Lovell to its Board of Directors and as a member of the Nominating and Corporate Governance Committee, effective March 22, 2021.
-
iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/24/2021
– Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12 th to discuss results –
-
International Harrington Prize Jointly Awarded to Drs. Warren Leonard and John O'Shea
3/24/2021
The eighth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Warren J. Leonard, MD, NHLBI, NIH Distinguished Investigator, and John J. O'Shea, MD, Scientific Director, NIAMS, NIH, for their respective contributions to the field of immunology, from fundamental discovery to therapeutic impact.
-
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
3/24/2021
2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective chemoprotection via p53 biomarker strategy; 50% of all cancer patients across multiple tumor types have a p53 mutation Achieved clinical proof-of-concept in Phase 1b study of ALRN-6924 in p53-mutated small cell lung cancer (SCLC)
-
Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy
3/24/2021
Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months.
-
Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
3/24/2021
Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors & Executive Team US$30M in gross proceeds from a private placement closed in November C$29.1M in proceeds from long-term loan from SALP in September
-
The American Diabetes Association Praises Introduction of Affordable Insulin for the COVID-19 Emergency Act and the Minority Diabetes Initiative Act
3/24/2021
Waters Bills Would Eliminate Cost-Sharing for Insulin-Dependent Seniors and Provide Needed Grants for Diabetes Prevention, Care and Treatment
-
Health Canada issues label change and guidance on the AstraZeneca COVID-19 vaccine
3/24/2021
Today, Health Canada updated the product monograph—or label—for the AstraZeneca and COVISHIELD COVID-19 vaccines to provide information on very rare reports of blood clots associated with low levels of blood platelets (i.e., thrombocytopenia) following immunization with the AstraZeneca vaccine
-
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 - Mar 24, 2021
3/24/2021
Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.